Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

BLRX $1.28 0.2700 +26.73%
BDSI $2.70 0.2500 +10.20%
TRIL $15.99 1.3300 +9.07%
NLNK $12.87 0.8600 +7.16%
BLCM $20.57 1.2600 +6.53%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

MNKD $0.61 -0.0664 -9.75%
MRTX $5.88 -0.5800 -8.98%
CALA $3.00 -0.1800 -5.66%
GALT $2.73 -0.1400 -4.88%
MTP $3.11 -0.1400 -4.31%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | Next > | Last >>

How Can A Company Market An Ovarian Cancer Screening Test If The FDA Says Women Shouldn't Use It?

(Forbes) Sept 11, 2016 - It is fitting that a Food and Drug Administration alert this week about tests marketed for ovarian cancer screening came out in September, which President Bill Clinton declared in 1998 to be National Ovarian Cancer Awareness Month.
read article 

Following Lawsuits, Millions in Fines & a Data Breach, 21st Century Oncology Gets New CEO

(WINK-TV/CBS News, Ch. 5 [Ft. Myers, FL]) Sept 10, 2016 - Cancer-care giant 21st Century Oncology appointed a new CEO on Friday, a move that comes after months of mishaps resulting in millions in fines and multiple lawsuits.
read article 

Top 15 Immuno-Oncology Collaborations

(GEN) Sept 12, 2016 - Nowhere in biopharma does the adage, "Follow the money" better apply, perhaps, than immuno-oncology, whose market size is expected to balloon to $19 billion in 2019 and $34 billion in 2024 (GlobalData).
read article 

ASCO Underscores Importance of 2017 MPFS and HOPPS Rulemaking as MACRA is Implemented

(ASCO in Action) Sept 9, 2016 - ASCO recently submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the agency's proposed rules regarding the 2017 Medicare Physician Fee Schedule (MPFS) and the 2017 Hospital Outpatient Prospective Payment System (HOPPS).
read article 

CMS Eases MACRA Quality Payment Program Timeline

(ACCCBuzz) Sept 12, 2016 - In response to considerable pressure from industry stakeholders, medical groups and policymakers, the Centers for Medicare & Medicaid Services (CMS) announced last week that it would provide increased flexibility for practices to report out and comply with new data and performance requirements under the Quality Payment Program (QPP), created by the Medicare Access and CHIP Reauthorization Act (MACRA) passed last year.
read article 

Effective Drug Is 'Tainted,' Unused in Pediatric Cancer

(Medscape Medical News) Sept 12, 2016 - In 1990, after Steven Lipshultz, MD, published the first-ever study on cardiotoxicity and pediatric chemotherapy for cancer, in the New England Journal of Medicine, he was invited to give grand rounds by David Nathan, MD, the head of pediatrics at Harvard Medical School and Boston Children's Hospital.
read article (free registration required) 

Cancer Cells May 'Piggyback' On Blood Platelets to Spread

(Cancer Research UK/Press Association) Sept 9, 2016 - French scientists have added to the growing evidence that platelets found in the blood may play a role in the spread of cancer cells.
read article 

Mount Sinai Researchers Identify New Therapeutic Target for Cancer

(Mount Sinai Hospital) Sept 9, 2016 - New research from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai identifies a protein that may be an unexplored target to develop new cancer therapies.
read press release 

How Ionising Radiation Damages DNA and Causes Cancer

(Wellcome Trust Sanger Institute [UK]) Sept 12, 2016 - For the first time, researchers from the Wellcome Trust Sanger Institute and their collaborators have been able to identify in human cancers two characteristic patterns of DNA damage caused by ionising radiation.
read press release 

Double Negative Leads to Big Positive Against Bladder Cancer Metastasis

(UCCC/Colorado Cancer Blogs) Sept 9, 2016 - The popular kids' card game "Exploding Kittens" teaches a concept critical to cancer science: When a player plays a "Nope" card, the subsequent player may lay another "Nope", thus creating a double-negative that becomes a positive, allowing the initial action to proceed.
read article 

Rexahn Pharmaceuticals Initiates Stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or Refractory Metastatic Pancreatic Cancer

(Yahoo! Finance) Sept 12, 2016 - Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the treatment of cancer, today announced it has initiated stage 2 of the Phase Ib/IIa clinical trial with the novel oral anti-cancer agent RX-3117 in relapsed or refractory pancreatic cancer patients.
read article 

Childhood Cancer Survivors Living Longer, Cancer-Free

(Reuters Health) Sept 9, 2016 - Due to better treatments and better monitoring, childhood cancer survivors are living longer, healthier lives, according to a study in the U.K.
read article 

TESARO Receives FDA Fast Track Designation for Niraparib and Initiates Rolling NDA Submission

(NASDAQ) Sept 12, 2016 - TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to niraparib for the treatment of patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
read article 

Voices of Patients and Oncologists Must be Heard, Study Says

(URMC) Sept 9, 2016 - Specifically training oncologists and their patients to have high-quality discussions improves communication, but troubling gaps still exist between the two groups, according to a new study in JAMA Oncology.
read press release 

Statins or Not? New Study Aims to Help Doctors and Patients Decide

(CNN) Sept 9, 2016 - The thought that comes to mind when you hear the word "statin" may depend on your age. Below the age of 40 and you may not have come across them, but for everyone else, these drugs can be something they love, or equally as often, loathe.
read article 

10 Must-Know Biotech Stock Events to Close Out 2016

(TheStreet) Sept 9, 2016 - Important clinical trial results in Alzheimer's, cancer, Crohn's disease and a big FDA decision for Sarepta expected before the end of the year.
read article 

Physicians Continue Move to Larger Practices: Study

(Healthcare Financial Management Association) Sept 8, 2016 - A new study confirms the ongoing trend of physician gravitation from small to large group practices.
read article 

Clinton’s Drug Proposals ‘Very Negative,’ Pfizer CEO Says

(Bloomberg) Sept 8, 2016 - The head of Pfizer Inc., America’s biggest drugmaker, said that Democratic presidential nominee Hillary Clinton’s proposals to contain the price of pharmaceuticals would be “very negative” for the industry and are a step toward single-payer health care.
read article 

No, Apple's New AirPods Won't Give You Cancer, Experts Say

(Los Angeles Times/Science Now blog) Sept 8, 2016 - The technology analysts have been calling Apple's decision to eliminate the earphone jack on its new iPhone 7 a risky business move.
read article (free registration required) 

Patients and Physicians at Hematology-Oncology Associates of Central New York Launch National Cancer Advocacy Group Chapter

(COA) Sept 8, 2016 - Today patients and leaders from the Hematology-Oncology Associates of Central New York (HOACNY) in East Syracuse, NY came together to launch a local chapter of the COA Patient Advocacy Network (CPAN), the national patient network of the Community Oncology Alliance (COA).
read press release 

Fate Therapeutics and Memorial Sloan Kettering Cancer Center Launch Partnership for Development of Off-the-Shelf T-Cell Immunotherapies

(Fate Therapeutics) Sept 7, 2016 - Fate Therapeutics, Inc., a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today a partnership with Memorial Sloan Kettering Cancer Center for the development of off-the-shelf T-cell product candidates using engineered pluripotent cell lines.
read corporate press release 

Cancer Survivorship Is On The Rise -- And That's Both Good News And Bad

(Forbes) Sept 9, 2016 - The Stand Up to Cancer telethon is tonight, and the hour-long TV event promises to offer a mix of inspiring cancer survivors and celebrities like Jon Hamm and Kristen Wiig hailing the accomplishments of the 8-year-old fundraising outfit, which has hauled in $370 million for oncology research so far.
read article 

Tyler Jacks, Cancer Moonshot Panel Co-Chair, Discusses Roadmap

(Xconomy National) Sept 9, 2016 - This week, a panel of 28 scientists presented the National Cancer Institute's National Cancer Advisory Board a set of recommendations and national priorities for basic research, clinical trial practice, and drug development. In an interview with Xconomy, panel co-chair Tyler Jacks acknowledged the recommendations were broad, with many details yet to be worked out.
read article 

Insurance Status Impacts Survival In Men With Testicular Cancer

(Dana-Farber Cancer Institute) Sept 8, 2016 - Men with testicular cancer who were uninsured or on Medicaid had a higher risk of death from what is normally a curable disease than insured patients, a new study found.
read press release 

Sugar Transforms a Traditional Chinese Medicine Into a Cruise Missile

(Johns Hopkins Medicine) Sept 7, 2016 - Anticancer compound becomes more soluble and selective after glucose is attached.
read press release